BRCA-Lung Immunotherapy Eligibility Explorer
BRCA1/2 mutations in lung adenocarcinoma predict better responses to immune checkpoint blockade despite worse overall prognosis — creating a paradox that clinicians need tools to navigate when making immunotherapy decisions for NSCLC patients.
BRCA-Lung Immunotherapy Eligibility Explorer
BRCA1/2 mutations in lung adenocarcinoma predict better responses to immune checkpoint blockade despite worse overall prognosis — creating a paradox that clinicians need tools to navigate when making immunotherapy decisions for NSCLC patients.
Build a clinical decision-support resource that helps oncologists interpret the immunotherapy implications of BRCA1/2 mutations in lung adenocarcinoma patients. The tool would synthesize evidence on how BRCA mutation status (type, BRCA1 vs BRCA2, somatic vs germline) correlates with tumor microenvironment features, ICB response rates, and overall survival in NSCLC. It would present this in an accessible format — not raw data, but structured clinical guidance with literature citations.
The interface would allow users to enter a patient's mutation profile and receive a summary of relevant evidence: what immune cell composition to expect, which T cell subsets (Trm populations) are prognostically important, and what published studies show about ICB outcomes in similar patients. The tool would also flag when BRCA testing hasn't been done and could meaningfully influence treatment decisions.
This matters today because BRCA testing in lung cancer is not yet standard practice — it's primarily ordered in breast/ovarian contexts. As evidence accumulates that BRCA status predicts immunotherapy outcomes in NSCLC, clinicians need accessible tools to understand and act on this information, and patients deserve to know whether their tumor genetics might predict response to available therapies.
Who Is This For?
Thoracic oncologists, molecular tumor boards, and genetic counselors working with NSCLC patients who need synthesized guidance on BRCA mutation implications for immunotherapy decisions.
Skills & Tools Needed
- Clinical oncology knowledge (NSCLC, immunotherapy, BRCA biology)
- Literature synthesis and evidence grading
- Web application development
- Medical writing for clinician-facing interfaces
- Basic bioinformatics for mutation annotation
Feasibility
high — This is primarily a content synthesis and presentation challenge — the underlying science exists in published literature and requires curation and a clean web interface rather than novel data generation.
